← Eichor
Condition: Pik3Ca Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pik3Ca Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Phase 2 · 33 location(s) · Hoffmann-La Roche · NCT07054190A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer
Phase 3 · 338 location(s) · Eli Lilly and Company · NCT07174336A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tu
Phase 1 · 37 location(s) · Relay Therapeutics, Inc. · NCT05216432Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Phase 2/Phase 3 · 60 location(s) · Novartis Pharmaceuticals · NCT05948943Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1/Phase 2 · 10 location(s) · SynDevRx, Inc. · NCT05455619A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated,
Phase N/A · 28 location(s) · Hoffmann-La Roche · NCT07347600A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined Wit
Phase 3 · 2 location(s) · Risen (Suzhou) Pharma Tech Co., Ltd. · NCT07207070First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
Phase 2 · 49 location(s) · Hoffmann-La Roche · NCT07405801GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT07407504Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI
Phase 3 · 211 location(s) · Relay Therapeutics, Inc. · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Le
Phase 3 · 232 location(s) · Hoffmann-La Roche · NCT06790693Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Ensem Therapeutics · NCT06993844To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Phase 2 · 30 location(s) · Hoffmann-La Roche · NCT07368998A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With
Phase 3 · 192 location(s) · Hoffmann-La Roche · NCT05894239A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Phase 2 · 2 location(s) · Murdoch Childrens Research Institute · NCT05983159Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With A
Phase 2 · 18 location(s) · Faeth Therapeutics · NCT06463028Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · 24 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spe
Phase 2 · 34 location(s) · Relay Therapeutics, Inc. · NCT06789913Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Canc
Phase 1/Phase 2 · 7 location(s) · Faeth Therapeutics · NCT07558733Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Phase 1 · 5 location(s) · Regor Pharmaceuticals Inc. · NCT07524322A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Phase 1 · 50 location(s) · Eli Lilly and Company · NCT05307705
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.